Inbiomotion's MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival
/PRNewswire/ -- Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III)...
Source: prnewswire.com